Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bexxar (Corixa/GlaxoSmithKline).

Bruce Cheson1

  • 1Medicine Section, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA. chesonb@ctep.nci.nih.gov

Current Opinion in Investigational Drugs (London, England : 2000)
|June 11, 2002
PubMed
Summary

Bexxar, a radiolabeled antibody, shows high response rates for non-Hodgkin's lymphoma. While effective, potential complications like myelosuppression require careful monitoring during treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Global Challenges After a Global Challenge: Lessons Learned from the COVID-19 Pandemic.

Advances in experimental medicine and biology·2024
Same author

Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022
Same author

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 1-Clinical).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022
Same author

Application of the Lugano Classification for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The PRoLoG Consensus Initiative (Part 2-Technical).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2022
Same author

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma.

Blood and lymphatic cancer : targets and therapy·2021
Same author

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy.

Blood and lymphatic cancer : targets and therapy·2020

Area of Science:

  • Oncology
  • Immunotherapy
  • Radiopharmaceuticals

Background:

  • Bexxar (131I tositumomab) is an anti-CD20 monoclonal antibody therapy.
  • It is indicated for relapsed and refractory follicular/low-grade and transformed non-Hodgkin's lymphoma.
  • Prior treatments include chemotherapy or rituximab.

Purpose of the Study:

  • To evaluate the efficacy and safety of Bexxar.
  • To define the role of this novel agent in clinical practice.
  • To assess response rates and durability of remissions.

Main Methods:

  • Utilizing phase II and III clinical trials.
  • Administering radiolabeled anti-CD20 monoclonal antibody therapy.
  • Monitoring patient responses and adverse events.

Main Results:

  • High response rates observed in patients.
  • Durable complete remissions achieved.
  • Potential complications include myelosuppression, secondary acute leukemia, myelodysplasia, and hypothyroidism.

Conclusions:

  • Bexxar demonstrates significant efficacy in treating specific non-Hodgkin's lymphoma subtypes.
  • The agent offers a promising therapeutic option for patients with relapsed or refractory disease.
  • Careful monitoring for adverse events is crucial for patient management.

Related Experiment Videos